Aledade
PrivateLast Round
Debt
Dec 1, 2025
Est. Valuation
$3.5B
Total Funding Raised
$1.12B
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Aledade is a healthtech company that provides a platform and services for primary care organizations to improve patient outcomes and succeed in value-based care models.
Sector
Healthcare & Life Sciences
Verticals
Healthcare Analytics, Vertical SaaS, Revenue Cycle, Patient Engagement, Compliance & Risk
Business Model
B2B
Customer Profile
Revenue Share, Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aledade Comparables
Compare Aledade with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vytalize Health | 85% | |
| Astrana Health | 84% | |
| Privia Health Group Inc | 84% |
Aledade Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Dec 1, 2025 | ||||
| Series F | Jun 21, 2023 | ||||
| Series E | Jun 6, 2022 | ||||
| Series D | Jan 19, 2021 | ||||
| Series C | Apr 20, 2020 | ||||
Series C Extension | Oct 23, 2018 |
Key People
Founding team and executive leadership
Aledade Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OMERS | Series C, Series E, Series F |
| GV | Series B Extension, Series D, Series C, Series E |
| TEDCO | Series B Extension |
| Fidelity Management & Research Company | Series F, Series E |
| OMERS Growth Equity | Series F, Series D, Series C, Series E |
| Avidity Partners | Series F, Series E |
| Biomatics Capital Partners | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 24, 2026
Job posting suggests preparation for public-company reporting and SOX controls.
- Apr 15, 2026
Oraida Roman appointed as new Chief Commercial Officer.
Recent news
Latest coverage and updates
- hiresSep 9, 2026
Aledade hired Sashi Moodley as chief medical officer on Sep 9th '26.
- hiresSep 9, 2026
Aledade hired Kim Wittman as chief people officer on Sep 9th '26.
- hiresJul 14, 2026
Aledade hired Daren Thayne as chief technology officer on Jul 14th '26.
- hiresJul 14, 2026
Aledade hired Josh C. Mandel as chief scientist on Aug 1st '26.
Aledade Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Aledade's valuation, stock price, and market status.
Is Aledade a public or private company?
Aledade is a private company.
What is the current stock price of Aledade?
Aledade is a private company with no public stock price. No recent secondary market data is available.
How much is Aledade worth (valuation)?
Aledade's valuation is estimated at $3.5B based on funding round data.
Can I buy Aledade stock?
Aledade shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Aledade's last funding round?
Aledade's most recent funding round was Debt on June 21, 2023.
Who are the main investors in Aledade?
Key investors in Aledade include OMERS, OMERS Growth Equity, Biomatics Capital Partners, ARCH Venture Partners, Ares Management.
Will Aledade IPO soon?
No public IPO plans have been announced for Aledade.
How can I track Aledade secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Aledade's secondary market activity and sign up for updates.